Stock Analysis

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

ENXTPA:BIM
Source: Shutterstock

The market for bioMérieux S.A.'s (EPA:BIM) shares didn't move much after it posted weak earnings recently. We did some digging, and we believe the earnings are stronger than they seem.

See our latest analysis for bioMérieux

earnings-and-revenue-history
ENXTPA:BIM Earnings and Revenue History September 15th 2023

How Do Unusual Items Influence Profit?

For anyone who wants to understand bioMérieux's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by €85m due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If bioMérieux doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On bioMérieux's Profit Performance

Because unusual items detracted from bioMérieux's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think bioMérieux's earnings potential is at least as good as it seems, and maybe even better! And the EPS is up 27% annually, over the last three years. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example - bioMérieux has 1 warning sign we think you should be aware of.

Today we've zoomed in on a single data point to better understand the nature of bioMérieux's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.